Researchers identified a new blood-based biomarker test measuring structural changes in proteins for Alzheimer's disease, published in Nature Aging.
The study analyzed plasma from 520 participants using mass spectrometry and machine learning, linking changes to ApoE genetic risk, symptom severity, and sex differences.
A three-protein panel (C1QA, CLUS, ApoB) distinguishes healthy controls, mild cognitive impairment, and Alzheimer's with 83.44% accuracy, outperforming quantity-based tests.
The panel tracks disease progression longitudinally with 86% accuracy and reveals sex-specific patterns in neuropsychiatric symptoms.
Findings supported by NIH's National Institute on Aging, led by Dr. John Yates at Scripps Research Institute.